Gattex (teduglutide) / Takeda - LARVOL DELTA

Therapeutic interventions targeting enteropathy in severe acute malnutrition modulate systemic and vascular inflammation and epithelial regeneration. (PubMed, EBioMedicine) - "Interventions aimed at ameliorating malnutrition enteropathy showed plausible effects on biomarkers of inflammation and epithelial regeneration, demonstrating an interdependence of systemic inflammation and enteropathy markers seen in structural analysis. Given the interplay between inflammation and tissue restoration in malnutrition, this mechanism of action supports larger trials to determine the clinical benefits of interventions, either alone or in combination, in children with complicated SAM."

Journal • Inflammation • Metabolic Disorders • CD14 • IGFBP3 • IL1R1 • VEGFA

GATTEX KAB: A Survey to Assess Participants' and Physicians' Knowledge, Attitudes and Behavior When Using GATTEX (clinicaltrials.gov) - P=N/A | N=600 | Recruiting | Sponsor: Takeda | Trial completion date: Dec 2024 ➔ Dec 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2026

Trial completion date • Trial primary completion date • Gastrointestinal Disorder • Short Bowel Syndrome

Novel homozygous nonsense mutation in glucagon-like peptide-2 receptor gene resulting in severe human illness. (PubMed, JPGN Rep) - "Trio-whole genome sequencing revealed homozygous nonsense variants resulting in nonfunctional GLP2R. This is the first known human documented with a GLP2R-deficient phenotype, resulting in clinical illness, which correlates with the findings in the GLP2R mouse knockout model and furthers our understanding of GLP2R and the action of teduglutide, a GLP2 analog used for the treatment of short bowel syndrome."

Journal • Critical care • Gastrointestinal Disorder • Infectious Disease • Metabolic Disorders • Pediatrics • Short Bowel Syndrome

Home Parenteral Support in Chronic Intestinal Failure-First Results from a Pioneer Portuguese Intestinal Failure Center. (PubMed, Nutrients) - "The conditions underlying IF varied, with SBS being the most frequent condition. HPS improved the BMI, allowing considerable survival. Despite the complications and one attributable death, HPS was safe, even when relying on patient self-care."

Journal • Retrospective data • Gastrointestinal Disorder • Infectious Disease • Short Bowel Syndrome

Use of glucagon-like polypeptide 2 analogs for intestinal failure. (PubMed, Expert Opin Pharmacother) - "More recently, ultralong acting GLP-2 analogs with half-lives of 70-80 hours can improve gastrointestinal function in surgically foreshortened bowel with only one injection every three to seven days. Future research is likely to focus upon the potential complementary role of GLP-1 and GLP-2 in treating short bowel syndrome."

Journal • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome

Real-world experience with glucagon-like peptide 2 analogues in patients with short bowel syndrome and chronic intestinal failure: results from an international survey in expert intestinal failure centers. (PubMed, Clin Nutr ESPEN) - "The results of this survey completed by expert IF centers show the real-life use of GLP-2 analogues in clinical practice. Key learning points identified include the accounting for a period of intestinal adaptation before starting GLP-2 analogues and not stopping the treatment too early in case of non-response. The best strategy in case of adverse effects should be studied further."

Journal • Real-world • Real-world evidence • Gastrointestinal Disorder • Short Bowel Syndrome

Complications of IPEX Syndrome with Crohn's-Like Enterocolonopathy Resulting in Short Gut Syndrome (ACG 2024) - "His symptoms improved with bowel rest and IV fluids, and he was discharged with teduglutide and outpatient follow up with GI and general surgery...A multidisciplinary team of surgery, gastroenterology, and nutrition should be closely following these patients to prevent potentially severe complications of short gut syndrome. Figure: Transition point seen proximal to the midline ileostomy, suggesting possible ileus versus SBO."

Atopic Dermatitis • Crohn's disease • Dermatology • Diabetes • Endocrine Disorders • Gastroenterology • Immunology • Metabolic Disorders • Pain • Short Bowel Syndrome • FOXP3

Effect of teduglutide, a glucagon-like peptide-2 analog, in eosinophilic enterocolitis: a case report. (PubMed, Front Pediatr) - "We found that teduglutide had an anti-inflammatory effect in this patient with eosinophilic gastrointestinal disease associated with short bowel syndrome. This report is the first to describe use of teduglutide in the treatment of eosinophilic gastrointestinal disease."

Journal • Gastroenterology • Gastrointestinal Disorder • Short Bowel Syndrome

LONG-TERM SAFETY AND EFFECTIVENESS OF TEDUGLUTIDE IN PAEDIATRIC PATIENTS WITH SHORT BOWEL SYNDROME-ASSOCIATED INTESTINAL FAILURE: AN OBSERVATIONAL, PROSPECTIVE, MULTICENTRE REGISTRY (UEGW 2024) - P | "This 6-year interim analysis of real-world data from a large cohort of paediatric patients with SBS-IF supports that the safety profile of TED is consistent with the previous 5-year follow-up and suggests that TED improves intestinal adaptation in paediatric patients with SBS-IF over a 3-year period."

Clinical • Observational data • Colon Cancer • Colonic Polyps • Colorectal Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • Immunology • Oncology • Pain • Pediatrics • Short Bowel Syndrome • Solid Tumor

TEDUGLUTIDE REVERSES INTESTINAL FAILURE IN PERCC1-ASSOCIATED ENTEROPATHY- A CASE REPORT (UEGW 2024) - "Hormone replacement therapy with the GLP-2 analogue teduglutide resulted in prompt cessation of PN, resolution of hyperphagia, markedly improved weight gain and 10-fold reduction in fat malabsorption.We report successful achievement of enteral autonomy in a patient with PERCC1-associated enteropathy and IF using the GLP-2 analogue teduglutide. These results have important implications for the pathogenesis and treatment of IF in patients with PERCC1-associated enteropathy and have therapeutic applicability to patients with enteroendocrine hormone deficiency from other congenital or acquired causes."

Case report • Clinical • Gastrointestinal Cancer • Oncology • GAST • PPY

TEDUGLUTIDE FOR THE TREATMENT OF SHORT BOWEL SYNDROME IN CROHN'S DISEASE PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS (UEGW 2024) - "Teduglutide is a good therapeutic option for patients with SBS in the subgroup of CD patients, improving PS reduction and discontinuation and leading to better quality of life of these patients."

Retrospective data • Review • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Short Bowel Syndrome

ENDOSCOPIC SMALL BOWEL SURVEILLANCE IN PATIENTS WITH SHORT BOWEL SYNDROME IN TREATMENT WITH TEDUGLUTIDE (UEGW 2024) - "DBE surveillance for small bowel malignancy in SBS patients undergoing TED treatment is feasible and effective. Total enteroscopy can be frequently achieved with a single endoscopy in these patients, allowing easy oncologic surveillance."

Clinical • Anesthesia • Colorectal Cancer • Crohn's disease • Gastrointestinal Cancer • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Oncology • Short Bowel Syndrome • Small Intestinal Carcinoma • Solid Tumor

Cost-Effectiveness of Teduglutide for Pediatric Patients with Short Bowel Syndrome in Japan, Including Caregiver Burden. (PubMed, Adv Ther) - "Incorporating the caregiver's burden in the cost-effectiveness analysis of teduglutide for pediatric patients with SBS provided a more comprehensive assessment of the value of teduglutide for patients, their families, and society. This approach enhances our understanding of the overall value of a treatment, especially for diseases with significant caregiver burden."

Cost effectiveness • HEOR • Journal • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome

The Epidemiology and Clinical Management of Short Bowel Syndrome and Chronic Intestinal Failure in Crohn's Disease in Italy: An IG-IBD Survey. (PubMed, Nutrients) - "The estimated prevalence of CIF in CD patients with small bowel involvement in Italy is 1%. The diagnosis and management practices for SBS and CIF are suboptimal, and TED use is limited."

Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Short Bowel Syndrome

Pancreatitis Associated With Teduglutide: A Disproportionality Analysis via the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. (PubMed, Cureus) - "Conclusion The results reveal a statistically significant association between pancreatitis risk and teduglutide use. Our findings highlight the necessity for the careful monitoring of pancreatitis in patients undergoing teduglutide therapy going forward."

Adverse events • Journal • Gastrointestinal Disorder • Pancreatitis • Short Bowel Syndrome

The real-world analysis of adverse events with teduglutide: a pharmacovigilance study based on the FAERS database. (PubMed, Front Pharmacol) - "Our findings corroborate the AEs listed in the teduglutide prescribing information and additionally unveil new adverse reaction signals such as nephrolithiasis. These discoveries could aid in clinical monitoring and risk identification for teduglutide."

Adverse events • Journal • Real-world • Real-world evidence • Gastrointestinal Disorder • Infectious Disease • Nephrology • Renal Calculi • Short Bowel Syndrome

Retrospective review of growth in pediatric intestinal failure after weaning from parenteral nutrition. (PubMed, Nutr Clin Pract) - "We observed stable growth with limited catch-up after PN weaning, with minimal variation by diagnosis, and during teduglutide therapy. Children who received an intestinal transplant experienced acceleration in weight and linear growth after weaning."

Journal • Retrospective data • Review • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome • Transplantation

Optimizing peripubertal growth in a child with short bowel syndrome on full oral feeding with glucagon-like peptide 2 analog. (PubMed, JPGN Rep) - "Teduglutide is a glucagon-like peptide 2 (GLP-2) analog which acts by increasing intestinal absorption of the remnant bowel for children with short bowel syndrome (SBS) dependent on parenteral nutrition...Pubertal spurt might be impaired in children with SBS on full oral feeding if the caloric need is not met by the residual intestinal absorption rate. GLP-2 analog might represent an option to sustain pubertal spurt in SBS children on full oral feeding with hyperphagia."

Journal • Gastrointestinal Disorder • Inflammatory Bowel Disease • Short Bowel Syndrome

Baseline Characteristics of Adult Patients Treated and Never Treated with Teduglutide in a Multinational Short Bowel Syndrome and Intestinal Failure Registry. (PubMed, Nutrients) - P=N/A | "Overall, ever-treated and never-treated patients had similar baseline characteristics. Differences between treatment groups may reflect variations in patient selection and degree of monitoring."

Journal • Colonic Polyps • Colorectal Cancer • Crohn's disease • Gastroenterology • Gastrointestinal Cancer • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Oncology • Short Bowel Syndrome • Solid Tumor

Management of Short Bowel Syndrome With Chronic Intestinal Failure: A Single-Center Experience in Portugal. (PubMed, Cureus) - "Two patients recently started teduglutide with good tolerance and need a reduction in HPN support...The existence of the commitment and interest of professionals involved in SBS/CIF at Centro Hospitalar Universitário de Santo António, Portugal, was a fundamental key to achieving those results. A multidisciplinary healthcare group for HPN support can be essential to ensuring these patients' survival and quality of life."

Journal • Cardiovascular • Congestive Heart Failure • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Hepatology • Infectious Disease • Liver Failure • Septic Shock • Short Bowel Syndrome • Thrombosis

Orally Delivered Stimulus-Sensitive Nanomedicine to Harness Teduglutide Efficacy in Inflammatory Bowel Disease. (PubMed, Small) - "Upon oral administration to colitis-induced mice, ROS-sensitive NPs are located in the colon, displaying healing capacity and reducing inflammation. Cleavable PEGylated NPs demonstrate effective potential in managing IBD symptoms and modulating the disease's progression."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease

Intestinal adaptation and rehabilitation in adults with short bowel syndrome. (PubMed, Curr Opin Clin Nutr Metab Care) - "Real-world data confirmed the teduglutide efficacy not only in weaning off IVS in accurately selected patients but also increased the alert on the risk of development of gastrointestinal polyps related to the drug; the impact of the therapy on patients' QoL deserves further studies and the cost-utility of the treatment is still uncertain. Some case reports highlighted the potential benefit of treatment with teduglutide in non-SBS gastrointestinal diseases, such as graft-versus-host disease, primary amyloidosis and refractory microscopic colitis. Phase 2 RCTs on safety and efficacy of two new long-acting GLP-2 analogues, glepaglutide and apraglutide, were published, and phase 3 RCTs have been completed."

Journal • Amyloidosis • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Immunology • Short Bowel Syndrome

Long-term teduglutide associated with improved response in pediatric short bowel syndrome-associated intestinal failure. (PubMed, J Pediatr Gastroenterol Nutr) - P3 | "In pediatric patients with SBS-IF, teduglutide treatment resulted in long-term reductions in PN/IV requirements. The degree of PN/IV volume reduction depended on the duration of teduglutide exposure, underlying bowel anatomy, and demographics."

Journal • Gastrointestinal Disorder • Pediatrics • Short Bowel Syndrome

PREDICTORS OF RESPONSE TO GLUCAGON-LIKE PEPTIDE 2 IN CHILDREN WITH SHORT BOWEL SYNDROME (ESPGHAN 2024) - "Female patients with better nutritional status are more likely to respond to teduglutide after 6 months. Liver dysfunction at diagnosis negatively influence 12-months treatment response. Monitoring hemoglobin and citrulline in the first 6 months might help to foresee treatment response."

Clinical • Gastrointestinal Disorder • Hepatology • Liver Failure • Short Bowel Syndrome

RECURRENT ENCEPHALOPATHY AND SEVERE METABOLIC ACIDOSIS IN A PATIENT WITH SHORT BOWEL: THINK D-LACTIC ACIDOSIS (ESPGHAN 2024) - "Began teduglutide therapy in June/2021, started to wean-off TPN, which was discontinued in August/2022, stopped teduglutide in January/2023.In August/2023, during vacation in Sardinia, high temperatures and a pasta based diet, he began episodes of vomiting and periods of altered consciousness.Observed in the local hospital with a severe metabolic acidosis...Daily TPN was restarted, with a one-week fasting period and intestinal decontamination with rifaximin, resulting in progressive improvement... Our case shows that D-lactate encephalopathy should be suspected and serum D-lactate measured whenever neurological symptoms occur in a patient with SBS. As D-lactic acid is not detected by conventional laboratory techniques, special laboratory tests must be performed when D-LA is suspected."

Clinical • CNS Disorders • Gastrointestinal Disorder • Metabolic Disorders • Rare Diseases • Short Bowel Syndrome